Advertisement

Topics

Search Results for "Sunitinib"

08:04 EDT 24th June 2017 | BioPortfolio

Matching Channels

None

Matching News

Individualized Sunitinib Dosing Improves Response, Survival in RCC

Individualizing first-line sunitinib was associated with improved response and survival times among patients with metastatic renal cell carcinoma.

Kidney cancer: Intermittent sunitinib is an effective renal carcinoma treatment

Intermittent sunitinib treatment is a feasible first-line approach in patients with renal cell carcinoma (RCC), providing a median progression-free survival duration of 37.6 months. Cyclic re-introduc...

Sunitinib Breaks Feasible for Treatment-Naive Metastatic RCC

Breaks from active sunitinib treatment for patients with treatment-naive metastatic renal cell carcinoma may be possible without effecting clinical efficacy.

[News] Intermittent sunitinib for metastatic renal cell carcinoma

Intermittent treatment with sunitinib is feasible for patients with metastatic renal cell carcinoma and does not seem to compromise its activity, suggest findings from a phase 2 study.

Sunitinib Malate Market: By Disease Pancreatic Neuroendocrine Tumors Kidney Cancer By Region Europe, North America, AsiaPacific Rest of the World RoWForecast 20162021 [Updated: 13092016] Prices from USD $5250

Sunitinib, developed and marketed as Sutent by Pfizer Inc and previously known as SU11248, is a smallmolecule medicine which has to be administered orally and has been proven to be effective in blocki...

Roche combo doubles RCC survival vs sunitinib

Human medicines European public assessment report (EPAR): Sutent, sunitinib, Revision: 30, Authorised

Genetic polymorphisms as predictive biomarker of survival in patients with gastrointestinal stromal tumors treated with sunitinib

Matching PubMed Articles

Diclofenac sex-divergent drug-drug interaction with Sunitinib: pharmacokinetics and tissue distribution in male and female mice.

Coadministration of diclofenac and sunitinib, tyrosine kinase inhibitor, led to sex-divergent pharmacokinetic drug-drug interaction outcomes. Male and female mice were administered 60 mg/kg PO suniti...

Efficacy of sequential therapies with sorafenib-sunitinib versus sunitinib-sorafenib in metastatic renal cell carcinoma: A systematic review and meta-analysis.

The most efficient sequence of targeted agents for metastatic renal cell carcinoma patients has yet to be identified. Whether the sequence of sorafenib and sunitinib really matters is controversial an...

A novel PDGF receptor inhibitor-eluting stent attenuates in-stent neointima formation in a rabbit carotid model.

A novel drug-eluting stent (DES) is required to target vascular smooth muscle cells (SMCs) without harming endothelial cells (ECs). Platelet-derived growth factor (PDGF) is critical for the proliferat...

Mixed Results for Sunitinib in Renal Cancer.

Two studies presented at the European Society for Medical Oncology 2016 Congress evaluated sunitinib in patients with renal cell carcinomas. The first found that the drug prevents recurrence in patien...

Sunitinib in the treatment of gastrointestinal stromal tumor: patient selection and perspectives.

Gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor of the gastrointestinal tract. In advanced setting and after progression to imatinib, the multi-targeted receptor tyrosine ki...

Search Whole site using Google

Loading
Quick Search
Advertisement
 
Advertisement Advertisement